|
Reference (author, year)
|
Region
|
Definition of CSU in weeks
|
Number of CSU patients undergoing testing
|
Number of healthy controls undergoing testing
|
% prevalence of anti-TPO antibody in study group
|
% prevalence of anti-TPO antibody in control group
|
Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days
|
|---|
|
Verneuil, 2004 [103]
|
France
|
–
|
45
|
30
|
17.8
|
3.3
|
Not stated
|
|
Gangemi, 2009 [104]
|
Italy
|
> 6
|
95
|
0
|
26.3
|
–
|
Not stated
|
|
Nuzzo, 2011 [105]
|
Italy
|
> 6
|
54
|
108
|
22.2
|
1.9
|
Not allowed
|
|
Alpay, 2013 [106]
|
Turkey
|
> 6
|
50
|
50
|
12
|
4
|
3 (AH)
|
|
Cho, 2013 [107]
|
United States
|
> 6
|
27
|
20
|
11.1
|
20.0
|
Not stated
|
|
Wan, 2013 [108]
|
Taiwan
|
> 6
|
60
|
40
|
8.3
|
0
|
Allowed (AH)
|
|
Yadav, 2013 [109]
|
India
|
> 6
|
80
|
0
|
17.5
|
–
|
3 (AH), 21 (SC)
|
|
Kim, 2016 [110]
|
Korea
|
> 6
|
184
|
0
|
13.6
|
–
|
Not stated
|
|
Czarnecka-Operacz, 2017 [111]
|
Poland
|
> 6
|
145
|
35
|
15.9
|
–
|
Not stated
|
|
Kasumagic-Halilovic, 2017 [112]
|
Bosnia and Herzegovina
|
> 6
|
70
|
70
|
30
|
1.4
|
Not stated
|
|
Schoepke, 2019 [98]
|
Multinational
|
> 6
|
182
|
0
|
20.9
|
–
|
3 (AH), 28 (SC)
|
- Anti-TPO antithyroid peroxidase, AH antihistamine, SC systemic corticosteroids
